One-third of AML patients have FLT3 mutations, and this mutation is associated with internal tandem duplication (ITD) in the JM domain of FLT3, promoting hyperactivation of tyrosine kinase signaling pathways coexisting with the expansion of the leukemia cell population [24, 25]. Here, FLT3 is linked to leukemia.